Literature DB >> 28640692

Comparison of Gadolinium Concentrations within Multiple Rat Organs after Intravenous Administration of Linear versus Macrocyclic Gadolinium Chelates.

Robert J McDonald1, Jennifer S McDonald1, Daying Dai1, Dana Schroeder1, Mark E Jentoft1, David L Murray1, Ramanathan Kadirvel1, Laurence J Eckel1, David F Kallmes1.   

Abstract

Purpose To compare gadolinium tissue concentrations of multiple linear and macrocyclic chelates in a rat model to better understand the scope and extent of tissue deposition following multiple intravenous doses of gadolinium-based contrast agent (GBCA). Materials and Methods In this Institutional Animal Care and Use Committee-approved study, healthy rats received 20 intravenous injections of 2.5 mmol gadolinium per kilogram (gadolinium-exposed group) or saline (control group) over a 26-day period. Unenhanced T1 signal intensities of the dentate nucleus were measured from magnetic resonance (MR) images obtained prior to GBCA injection and 3 days after final injection. Rat brain and renal, hepatic, and splenic tissues were harvested 7 days after final injection and subjected to inductively coupled plasma mass spectrometry and transmission electron microscopy for quantification and characterization of gadolinium deposits. Results Gadolinium deposition in brain tissue significantly varied with GBCA type (F = 31.2; P < .0001), with median concentrations of 0 μg gadolinium per gram of tissue (95% confidence interval [CI]: 0, 0.2) in gadoteridol-injected rats, 1.6 μg gadolinium per gram of tissue (95% CI: 0.9, 4.7) in gadobutrol-injected rats, 4.7 μg gadolinium per gram of tissue (95% CI: 3.5, 6.1) in gadobenate dimeglumine-injected rats, and 6.9 μg gadolinium per gram of tissue (95% CI: 6.2, 7.0) in gadodiamide-injected rats; a significant positive dose-signal intensity correlation was identified (ρ = 0.93; P < .0001). No detectable neural tissue deposition or MR imaging signal was observed in control rats (n = 6). Similar relative differences in gadolinium deposition were observed in renal, hepatic, and splenic tissues at much higher tissue concentrations (P < .0001). Gadolinium deposits were visualized directly in the endothelial capillary walls and neural interstitium in GBCA-injected rats, but not in control rats. Conclusion Tissue deposition of gadolinium was two- to fourfold higher following administration of the linear agents gadodiamide and gadobenate dimeglumine compared with the macrocyclic agents gadobutrol and gadoteridol. These findings suggest that organ tissue deposition is reduced but not eliminated following administration of macrocyclic GBCA chelates in lieu of linear chelates. © RSNA, 2017 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28640692     DOI: 10.1148/radiol.2017161594

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  55 in total

Review 1.  The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists.

Authors:  Mariane Le Fur; Peter Caravan
Journal:  Metallomics       Date:  2019-02-20       Impact factor: 4.526

2.  Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.

Authors:  Derek J Erstad; Ian A Ramsay; Veronica Clavijo Jordan; Mozhdeh Sojoodi; Bryan C Fuchs; Kenneth K Tanabe; Peter Caravan; Eric M Gale
Journal:  Invest Radiol       Date:  2019-11       Impact factor: 6.016

3.  Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2.

Authors:  Catherine Do; Viktor Drel; Chunyan Tan; Doug Lee; Brent Wagner
Journal:  J Invest Dermatol       Date:  2019-04-09       Impact factor: 8.551

4.  Deep Learning for Predicting Enhancing Lesions in Multiple Sclerosis from Noncontrast MRI.

Authors:  Ponnada A Narayana; Ivan Coronado; Sheeba J Sujit; Jerry S Wolinsky; Fred D Lublin; Refaat E Gabr
Journal:  Radiology       Date:  2019-12-17       Impact factor: 11.105

5.  Prognostic Predictions for Patients with Glioblastoma after Standard Treatment: Application of Contrast Leakage Information from DSC-MRI within Nonenhancing FLAIR High-Signal-Intensity Lesions.

Authors:  S H Kim; K H Cho; S H Choi; T M Kim; C K Park; S H Park; J K Won; I H Kim; S T Lee
Journal:  AJNR Am J Neuroradiol       Date:  2019-11-14       Impact factor: 3.825

6.  Impact of chelation timing on gadolinium deposition in rats after contrast administration.

Authors:  John P Prybylski; Carla Coste Sanchez; Michael Jay
Journal:  Magn Reson Imaging       Date:  2018-10-12       Impact factor: 2.546

7.  Increasing FLAIR signal intensity in the postoperative cavity predicts progression in gross-total resected high-grade gliomas.

Authors:  Guan-Min Quan; Yong-Li Zheng; Tao Yuan; Jian-Ming Lei
Journal:  J Neurooncol       Date:  2018-03-21       Impact factor: 4.130

8.  Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency.

Authors:  Ilona A Dekkers; Rick Roos; Aart J van der Molen
Journal:  Eur Radiol       Date:  2017-10-23       Impact factor: 5.315

9.  Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles.

Authors:  E A Wallnöfer; G C Thurner; C Kremser; H Talasz; M M Stollenwerk; A Helbok; N Klammsteiner; K Albrecht-Schgoer; H Dietrich; W Jaschke; P Debbage
Journal:  Histochem Cell Biol       Date:  2020-10-11       Impact factor: 4.304

10.  Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration.

Authors:  E Kanal; T J Patton; I Krefting; C Wang
Journal:  AJNR Am J Neuroradiol       Date:  2020-02-27       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.